fusidate de sodium pierre fabre
limedika, uab - natrio fuzidatas - tepalas - 20 mg/g - fusidic acid
fusidate de sodium pierre fabre
ideal trade links, uab - natrio fuzidatas - tepalas - 20 mg/g - fusidic acid
pan-penicillin g sodium
panpharma - benzilpenicilinas - milteliai injekciniam ar infuziniam tirpalui - 5 mln. tv; 1 mln. tv; 1 mtv; 5 mtv - benzylpenicillin
penicillin g sodium sandoz
sandoz gmbh - benzilpenicilinas - milteliai injekciniam ar infuziniam tirpalui - 1000000 tv - benzylpenicillin
dexamethasone sodium phosphate
niromed, uab - deksametazono natrio fosfatas - injekcinis ar infuzinis tirpalas - 4 mg/ml - dexamethasone
microlax
mcneil ab - sorbitolis/natrio citratas/natrio laurilsulfoacetatas - tiesiosios žarnos tirpalas - 625 mg/90 mg/9 mg/ml - sodium lauryl sulfoacetate, incl. combinations
microlax
limedika, uab - sorbitolis/natrio citratas/natrio laurilsulfoacetatas - tiesiosios žarnos tirpalas - 625 mg/90 mg/9 mg/ml - sodium lauryl sulfoacetate, incl. combinations
microlax
limedika, uab - sorbitolis/natrio citratas/natrio laurilsulfoacetatas - tiesiosios žarnos tirpalas - 625 mg/90 mg/9 mg/ml - sodium lauryl sulfoacetate, incl. combinations
microlax
lex ano, uab - sorbitolis/natrio citratas/natrio laurilsulfoacetatas - tiesiosios žarnos tirpalas - 625 mg/90 mg/9 mg/ml - sodium lauryl sulfoacetate, incl. combinations
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - visi kiti gydomieji produktai - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.